Hemay5394
/ Ganzhou Hemay Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 17, 2026
To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=90 | Not yet recruiting | Sponsor: Hemay Pharmaceutical PTY. LTD.
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1